Evidence map›Paper›PMID 37343519›Full record

ArticleCell reports. Medicine2023

Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal.

Anne Gompel, Cynthia A Stuenkel

Open access · goldAbstract read
In one paragraph

Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Effects of menopause on temperature regulation.Temperature (Austin, Tex.) · 2025
    Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Anne GompelUnité de Gynécologie, Port Royal- Cochin Hôpital, Université Paris Cité, Paris, France. Electronic address: anne.gompel@parisdesartes.fr.
Cynthia A StuenkelDepartment of Medicine, Division of Endocrinology and Metabolism, University of California, San Diego, School of Medicine, La Jolla, CA, USA.
Université Paris Cité · FRUniversity of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fezolinetant is a neurokinin 3 receptor antagonist under investigation for treatment of menopausal symptoms. In a recent study, Lederman and colleagues

Indexed as

Heterocyclic Compounds, 2-RingHot FlashesFemaleHumansMenopauseReceptors, Neurokinin-3ThiadiazolesfezolinetantHeterocyclic Compounds, 2-RingReceptors, Neurokinin-3Thiadiazoles

Identifiers

PMID37343519
PMCPMC10313926
OpenAlexW4381436826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.